Have your own idea? Try our Stock Screener
Hong Kong (HSI) Life Sciences Industry Analysis
UpdatedMar 15, 2025
DataAggregated Company Financials
Companies9
- 7D6.9%
- 3M38.9%
- 1Y57.8%
- YTD38.8%
Over the last 7 days, the Life Sciences industry has dropped 1.3%, driven by Genscript Biotech declining 6.7%. In contrast, WuXi Biologics (Cayman) has gained 12%. This takes the industry's 12 month performance to a gain of 34%. Looking forward, earnings are forecast to grow by 36% annually.
Industry Valuation and Performance
Has the Hong Kong Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 15 Mar 2025 | HK$213.8b | HK$32.7b | -HK$202,787,999.22 | 48.7x | -1054.2x | 6.5x |
| Mon, 10 Feb 2025 | HK$175.1b | HK$35.8b | -HK$1,060,966,493.57 | 57.9x | -165.1x | 4.9x |
| Wed, 08 Jan 2025 | HK$147.5b | HK$35.6b | -HK$1,060,269,486.94 | 55.8x | -139.1x | 4.1x |
| Fri, 06 Dec 2024 | HK$147.7b | HK$35.9b | -HK$1,058,992,109.56 | 51.8x | -139.5x | 4.1x |
| Sun, 03 Nov 2024 | HK$153.9b | HK$35.7b | -HK$660,755,913.74 | 38x | -232.9x | 4.3x |
| Tue, 01 Oct 2024 | HK$175.6b | HK$36.1b | -HK$649,378,648.95 | 35.5x | -270.5x | 4.9x |
| Thu, 29 Aug 2024 | HK$95.9b | HK$35.8b | HK$2.0b | 15.2x | 47.4x | 2.7x |
| Sat, 27 Jul 2024 | HK$90.7b | HK$33.4b | HK$3.1b | 16.8x | 29.4x | 2.7x |
| Mon, 24 Jun 2024 | HK$91.1b | HK$33.4b | HK$3.1b | 21.8x | 29.6x | 2.7x |
| Wed, 22 May 2024 | HK$102.5b | HK$33.5b | HK$3.1b | 30x | 33.2x | 3.1x |
| Fri, 19 Apr 2024 | HK$104.7b | HK$33.6b | HK$3.1b | 32.5x | 33.8x | 3.1x |
| Sun, 17 Mar 2024 | HK$120.3b | HK$33.3b | HK$3.7b | 47.6x | 32.7x | 3.6x |
| Tue, 13 Feb 2024 | HK$124.0b | HK$32.3b | HK$3.0b | 46.7x | 41.7x | 3.8x |
| Thu, 11 Jan 2024 | HK$198.5b | HK$32.4b | HK$3.0b | 85.4x | 66.4x | 6.1x |
| Sat, 09 Dec 2023 | HK$208.6b | HK$32.4b | HK$3.0b | 81.3x | 69.7x | 6.4x |
| Mon, 06 Nov 2023 | HK$259.5b | HK$30.1b | HK$2.7b | 45.8x | 97.2x | 8.6x |
| Wed, 04 Oct 2023 | HK$245.6b | HK$30.2b | HK$2.7b | 42.4x | 91.8x | 8.1x |
| Fri, 01 Sep 2023 | HK$235.0b | HK$30.3b | HK$2.7b | 42x | 87.4x | 7.8x |
| Sun, 30 Jul 2023 | HK$236.8b | HK$28.5b | HK$2.7b | 23.8x | 86.2x | 8.3x |
| Tue, 27 Jun 2023 | HK$210.9b | HK$28.4b | HK$2.7b | 20.4x | 77.8x | 7.4x |
| Thu, 25 May 2023 | HK$235.8b | HK$28.9b | HK$2.8b | 21.9x | 83.6x | 8.1x |
| Sat, 22 Apr 2023 | HK$265.7b | HK$29.5b | HK$2.9b | 25.1x | 90.4x | 9x |
| Mon, 20 Mar 2023 | HK$252.9b | HK$26.4b | HK$2.1b | 23.6x | 122.7x | 9.6x |
| Wed, 15 Feb 2023 | HK$322.6b | HK$26.6b | HK$2.1b | 25.5x | 152.6x | 12.1x |
| Fri, 13 Jan 2023 | HK$354.6b | HK$26.6b | HK$2.2b | 26.5x | 164.8x | 13.3x |
| Sun, 11 Dec 2022 | HK$288.2b | HK$26.0b | HK$2.0b | 27.9x | 144.4x | 11.1x |
| Tue, 08 Nov 2022 | HK$255.7b | HK$25.6b | HK$1.9b | 24.8x | 137.4x | 10x |
| Thu, 06 Oct 2022 | HK$260.8b | HK$25.7b | HK$1.9b | 21x | 136.8x | 10.1x |
| Sat, 03 Sep 2022 | HK$343.4b | HK$26.3b | HK$2.0b | 27.3x | 167.5x | 13x |
| Mon, 01 Aug 2022 | HK$388.7b | HK$22.3b | HK$2.1b | 12x | 189.6x | 17.4x |
| Wed, 29 Jun 2022 | HK$390.4b | HK$22.4b | HK$2.1b | 16.1x | 187.2x | 17.4x |
| Fri, 27 May 2022 | HK$279.7b | HK$22.5b | HK$2.1b | 13.2x | 132.3x | 12.4x |
| Sun, 24 Apr 2022 | HK$296.8b | HK$22.9b | HK$2.2b | 14.3x | 133.1x | 12.9x |
| Tue, 22 Mar 2022 | HK$301.2b | HK$19.2b | HK$1.5b | 20.6x | 197.6x | 15.7x |
Price to Earnings Ratio
197.6x
Current Industry PE
- Investors are pessimistic on the Hong Kong Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 8.1x is higher than the industry's current PS ratio of 6.0x.
Past Earnings Growth
- Total earnings for the Life Sciences industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 20% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 0.63% | |
| Healthcare | 1.34% | |
| Life Sciences | 6.91% | |
| Clinical Research and Equipment | 6.91% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$26.65 | 12.2% +HK$11.9b | 84.6% | PE38.6x | |
| 2268 WuXi XDC Cayman | HK$38.85 | 8.8% +HK$3.8b | 148.7% | PE72.9x | |
| 1873 Viva Biotech Holdings | HK$1.70 | 23.2% +HK$675.9m | 233.3% | PS1.7x | |
| 1521 Frontage Holdings | HK$1.14 | 9.6% +HK$202.4m | -26.5% | PE48.7x | |
| 6118 Austar Lifesciences | HK$0.86 | 4.9% +HK$20.5m | -37.2% | PS0.3x |